BMS-P5

BMS-P5 is a selective and orally active peptidylarginine deiminase 4 (PAD4) inhibitor with an IC50 of 98 nM. BMS-P5 shows selective for PAD4 over PAD1, PAD2, and PAD3. BMS-P5 blocks multiple myeloma (MM) -induced neutrophil extracellular trap (NET) formation and delays progression of MM in a syngeneic mouse model[1].

Product Specifications

CAS Number

[1549811-36-0]

UNSPSC

12352005

Target

Protein Arginine Deiminase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bms-p5.html

Purity

99.23

Solubility

DMSO : 35 mg/mL (ultrasonic)

Smiles

O=C(N1[C@@H](C)CC[C@@H](N)C1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC6CC6)N3C)=C2.[H]Cl

Molecular Formula

C27H33ClN6O2

Molecular Weight

509.04

References & Citations

[1]Marina Li, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19 (7) :1530-1538.